Reporting in Nature, Gray and colleagues identify and characterize a selective allosteric inhibitor of BCR–ABL, GNF-5, that cooperates with ATP competitive inhibitors to inhibit both wild-type ...

Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008.

Enliven's initial phase 1 data for ELVN-001 in CML shows promising tolerability and activity in heavily pretreated patients. But read why ELVN stock is a Sell.

Ascentage Pharma Group International (OTCMKTS:ASPHF – Get Free Report) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest ...

Unlike in mice, secondary BCR-ABL kinase mutations are common in Ph+ ... this hypothesis could be quickly tested with inhibitors of downstream JAK kinases, several of which are expected to enter ...

Enliven Therapeutics' ELVN-001 shows promising results for CML patients. Click here to read what makes ELVN stock a ...

Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR ...

The Company granted options to purchase 9,000 shares of Terns common stock to the new employee. The options have a 10-year term and an exercise price per share equal to $5.54, which was the closing ...

Olverembatinib is a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development Program in China and the first third-generation BCR-ABL inhibitor approved by the ...

A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on ...

Olverembatinib is the first third-generation BCR-ABL inhibitor approved by China's National Medical Products Administration (NMPA). Innovent and Ascentage Pharma are mutually committed to the ...